聯繫方式：投資者關係
ir@davita.com
德維特公司
聯繫方式：投資者關係
ir@davita.com
DaVita Inc. 2024年第三季度業績
2024年10月29日，科羅拉多州丹佛——大都會公司（紐交所：DVA）宣佈了截至2024年9月30日的季度財務和運營結果。
「在爲我們的患者提供持續優質護理的過程中，我們交出了令人滿意的第三季度財務表現，」 DaVita Inc.首席執行官哈維爾·羅德里格斯說道。「且，在最近發生的嚴重暴風雨中，我要感謝我們患者和一線護理人員所展現的驚人韌性。」
2024年9月30日結束的季度財務和運營亮點：
•綜合收入爲32.64億美元。
•營業收入爲53500萬美元。
•每股攤薄收益爲$2.50，調整後的每股攤薄收益爲$2.59。
•經營性現金流爲8.1億美元，自由現金流爲5.55億美元。
•累計發行金額爲11億美元的增量A-1期貸款和總額爲10億美元的6.875%優先票據。 這些交易的部分收入用於償還2026年到期的約95000萬美元的B-1期貸款和我們循環信貸帳戶上的未清餘額。
•以每股147.20美元的平均價值回購了270萬股普通股。
| 截至三個月結束時 | 截至9月30日的九個月 | ||||||||||||||||||||||
| 2024年9月30日 | 2024年6月30日 | 2024 | 2023 | ||||||||||||||||||||
歸屬於德維特股份有限公司的淨利潤： | (單位：百萬美元，每股數據除外) | ||||||||||||||||||||||
| 淨收入 | $ | 215 | $ | 223 | $ | 677 | $ | 541 | |||||||||||||||
| 每股攤薄 | $ | 2.50 | $ | 2.50 | $ | 7.66 | $ | 5.80 | |||||||||||||||
調整後淨利潤(1) | $ | 222 | $ | 230 | $ | 657 | $ | 566 | |||||||||||||||
調整後每股攤薄收益(1) | $ | 2.59 | $ | 2.59 | $ | 7.43 | $ | 6.06 | |||||||||||||||
(1)關於非通用會計準則財務指標的定義，請參見題爲「非通用會計準則財務指標說明」和相關調和表，從第一頁開始。 15.
| 三個月結束了 | 截至9月30日的九個月 | ||||||||||||||||||||||||||||||||||||||||||||||
| 2024年9月30日 | 2024年6月30日 | 2024 | 2023 | ||||||||||||||||||||||||||||||||||||||||||||
| 金額 | 利潤 | 金額 | 利潤 | 金額 | 利潤 | 金額 | 利潤 | ||||||||||||||||||||||||||||||||||||||||
| 營業收入 | （以百萬美元計） | ||||||||||||||||||||||||||||||||||||||||||||||
| 營業收入 | $ | 535 | 16.4 | % | $ | 506 | 15.9 | % | $ | 1,525 | 16.0 | % | $ | 1,213 | 13.5 | % | |||||||||||||||||||||||||||||||
調整後的營業收入(1) | $ | 535 | 16.4 | % | $ | 506 | 15.9 | % | $ | 1,490 | 15.6 | % | $ | 1,252 | 13.9 | % | |||||||||||||||||||||||||||||||
(1)有關非通用會計準則財務指標的定義，請參閱標題爲「關於非通用會計準則財務指標的說明」和相關的調節開端的備註。 頁 15.
1
美國透析指標：
成交量: 2024年第三季度美國透析治療總次數爲7,350,784次，平均每天93,048次治療，與2024年第二季度相比，每天減少了0.1%，與2023年第三季度相比，非收購的規範化治療增長下降了0.2%。
| 三個月結束了 | 季度 改變 | 九個月已結束 | 年初至今 改變 | ||||||||||||||||||||||||||||||||
| 9月30日 2024 | 6月30日 2024 | 9月30日 2024 | 9月30日 2023 | ||||||||||||||||||||||||||||||||
| （以百萬美元計，每個治療數據除外） | |||||||||||||||||||||||||||||||||||
| 每次治療的收入 | $ | 394.49 | $ | 390.22 | $ | 4.27 | $ | 389.79 | $ | 374.46 | $ | 15.33 | |||||||||||||||||||||||
| 每次治療的患者護理費用 | $ | 257.46 | $ | 255.25 | $ | 2.21 | $ | 255.96 | $ | 253.30 | $ | 2.66 | |||||||||||||||||||||||
| 一般和行政 | $ | 301 | $ | 282 | $ | 19 | $ | 858 | $ | 819 | $ | 39 | |||||||||||||||||||||||
以上表格變化的主要驅動因素如下：
毛利率：Q1/2024爲46%；Q1/2023爲44%；235個點子的提高。季度變化主要是由於平均報銷率和其他正常波動的增加所致。截至目前的變化主要是由於平均報銷率的增加，包括來自醫療保險的正常年度費率調整，以及收入循環改善、混合變化以及醫院住院透析率的增加。
病人護理費用： 季度變動主要是由於我們透析中心的增加的補償支出、健康福利支出以及其他直接營業費用。這些增加部分被保險費用、差旅費、專業費用和中心關閉成本的降低部分抵消。截至目前的年度變動主要是由於補償支出、健康福利支出和寵物-醫療產品費用的增加。這些增加部分被對慈善組織的捐款減少、合同工資和中心關閉成本的抵消部分抵消。
總和的一般管理和管理費用： 季度變化主要是由於增加的倡導成本、補償費用、IT相關費用、旅行費用和專業費用。這些增加部分被中心關閉成本的減少抵消。至今爲止的年度變化主要是由於補償費用的增加、倡導成本的增加，包括2023年收到的2022年倡導相關費用退款。推動這種變化的其他因素包括IT相關成本、合同工資、中心關閉成本和專業費用的增加。這些增加部分被減少的解僱費用和對慈善組織的捐款所抵消。
對本季度產生影響的項目：
停業成本。 在2022年第三季度，我們開始對門診診所的容量需求和利用率進行戰略審查，由於COVID-19大流行導致我們的病人收入顯著下降。這一審查持續到2023年，並導致過去幾個季度中心容量關閉的費用高於正常水平。這些容量關閉費用包括退役資產的淨損失、租賃終止費用、資產減值和加速折舊和攤銷。
在截至2024年9月30日的三個月和截至2024年9月30日的九個月內，我們爲美國透析中心關閉產生了約1830萬美元和4820萬美元的費用。 截至2024年9月30日的三個月內，這些中心的關閉增加了我們的患者護理成本350萬美元，我們的一般管理費用380萬美元，折舊和攤銷費用1100萬美元。 截至2024年9月30日的九個月內，這些中心的關閉增加了我們的患者護理成本1330萬美元，我們的一般管理費用1960萬美元，折舊和攤銷費用1530萬美元。
如先前披露的，我們已更新非通用會計準則的報告，不再在所有期間排除中心關閉成本，也適用於我們當前2024財年的指引。爲了便於比較，此前顯示的往期數據現在符合這一修訂後的呈現方式。
債務交易。 2024年8月，我們與我們的高級擔保信貸協議簽訂了第六次修訂。第六次修訂擴展了總額爲110000萬美元的額外A-1期貸款。公司還發行了總額爲100000萬美元的6.875% 2032年到期的優先票據。這些交易的淨收益部分被用於提前償還截至2026年到期的擬終端貸款b-1餘額，金額爲95000萬美元，以及未償還的循環信貸餘額和相關應計利息和費用。剩餘的借款增加了資產負債表上的現金，用於一般公司用途。
2
變革醫療。 在截至2024年9月30日的九個月內，由於變革醫療系統故障，我們遭遇了理賠處理延誤。因此，我們申請並獲得了聯合健康集團在臨時資金援助計劃下的無息資金支持。截至2024年9月30日，我們在該計劃下尚有12000萬美元的未償債務。根據該計劃提供的資金須在未來日期與變革醫療和公司共同同意的45個工作日內償還。
Share repurchases. During the three months ended September 30, 2024, we repurchased 2.7 million shares for $406 million, at an average price paid of $147.20 per share.
Subsequent to September 30, 2024 through October 25, 2024, the Company has repurchased 0.6 million shares of our common stock for $101 million at an average price paid of $160.77 per share.
Financial and operating metrics:
| Three months ended September 30, | Twelve months ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Cash flow: | (dollars in millions) | ||||||||||||||||||||||
| Operating cash flow | $ | 810 | $ | 661 | $ | 1,960 | $ | 1,918 | |||||||||||||||
Free cash flow(1) | $ | 555 | $ | 453 | $ | 1,139 | $ | 1,054 | |||||||||||||||
(1)For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page 15.
| Three months ended September 30, 2024 | Nine months ended September 30, 2024 | ||||||||||
| Effective income tax rate on: | |||||||||||
| Income | 20.8 | % | 19.3 | % | |||||||
Income attributable to DaVita Inc.(1) | 26.5 | % | 24.1 | % | |||||||
Adjusted income attributable to DaVita Inc.(1) | 26.5 | % | 25.0 | % | |||||||
(1)For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page 15.
Center activity: As of September 30, 2024, we provided dialysis services to a total of approximately 265,400 patients at 3,113 outpatient dialysis centers, of which 2,660 centers were located in the United States and 453 centers were located in 13 countries outside of the United States. During the third quarter of 2024, we opened three and closed 15 dialysis centers in the United States. We also acquired one, opened four and closed four dialysis centers outside of the United States during the third quarter of 2024.
Integrated kidney care (IKC): As of September 30, 2024, we had approximately 69,500 patients in risk-based integrated care arrangements representing approximately $5.4 billion in annualized medical spend. We also had an additional 13,900 patients in other integrated care arrangements; we do not include the medical spend for these patients in this annualized medical spend estimate. For an additional description of these metrics, see footnote 4 in the "Supplemental Financial Data" table below.
3
Outlook:
The following forward-looking measures and the underlying assumptions involve significant known and unknown risks and uncertainties, including those described below, and actual results may vary materially from these forward-looking measures. We do not provide guidance for operating income or diluted net income per share attributable to DaVita Inc. on a basis consistent with United States generally accepted accounting principles (GAAP) nor a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis because we are unable to predict certain items contained in the GAAP measures without unreasonable efforts. These current non-GAAP financial measures do not include certain items, including gains on changes in ownership interest and foreign currency fluctuations, which may be significant. The guidance for our effective income tax rate on adjusted income attributable to DaVita Inc. also excludes the amount of third-party owners' income and related taxes attributable to non-tax paying entities.
As previously disclosed, our 2024 guidance provided below no longer excludes center closure costs.
| 2024 guidance | |||||||||||
| Low | High | ||||||||||
| (dollars in millions, except per share data) | |||||||||||
| Adjusted operating income | $1,910 | $2,010 | |||||||||
| Adjusted diluted net income per share attributable to DaVita Inc. | $9.25 | $10.05 | |||||||||
| Free cash flow | $950 | $1,200 | |||||||||
We will be holding a conference call to discuss our results for the third quarter ended September 30, 2024, on October 29, 2024, at 5:00 p.m. Eastern Time. To join the conference call, please dial (877) 918-6630 from the U.S. or (517) 308-9042 from outside the U.S., and provide the operator the password "Earnings." This call is being webcast and can be accessed at the DaVita Investor Relations website investors.davita.com. A replay of the conference call will also be available at investors.davita.com for the following 30 days.
4
Forward looking statements
DaVita Inc. and its representatives may from time to time make written and oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements in this release, filings with the Securities and Exchange Commission (SEC), reports to stockholders and in meetings with investors and analysts. All statements in this release, during the related presentation or other meetings, other than statements of historical fact, are forward-looking statements and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the PSLRA. These forward-looking statements could include, among other things, statements about our balance sheet and liquidity, our expenses, revenues, billings and collections, patient census, availability or cost of supplies, including without limitation the impact of the reduction in clinical and other supplies delivered to DaVita by Baxter International Inc. or its subsidiaries (collectively, Baxter) due to closures of Baxter facilities following Hurricane Helene, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, the effects of the recent Change Healthcare (CHC) cybersecurity outage on us and our operations, current macroeconomic, marketplace and, labor market conditions, and overall impact on our patients and teammates, as well as other statements regarding our future operations, financial condition and prospects, capital allocation plans, expenses, cost saving initiatives, other strategic initiatives, use of contract labor, government and commercial payment rates, expectations related to value-based care (VBC), integrated kidney care (IKC), Medicare Advantage (MA) plan enrollment and our international operations, expectations regarding increased competition and marketplace changes, including those related to new or potential entrants in the dialysis and pre-dialysis marketplace and the potential impact of innovative technologies, drugs or other treatments on the dialysis industry, expectations regarding the impact of our continuing cost savings initiatives and our stock repurchase program, and statements related to our guidance and expectations for future periods and the assumptions underlying any such projections. All statements in this release, other than statements of historical fact, are forward-looking statements. Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "plan," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on DaVita's current expectations and are based solely on information available as of the date of this release. DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things:
•current macroeconomic and marketplace conditions, including, without limitation, the impact of global events and political or governmental volatility; the impact of the domestic political environment and related developments on the current healthcare marketplace, our patients and on our business; the continuing impact of the COVID-19 pandemic on our operations, reputation, financial condition and the chronic kidney disease (CKD) population and our patient population; supply chain challenges and disruptions, including without limitation with respect to certain key services provided to us and certain critical clinical supplies and equipment, and including any impacts on our supply chain as a result of natural disasters; the potential impact of new or potential entrants in the dialysis and pre-dialysis marketplace and potential impact of innovative technologies, drugs, or other treatments on our patients and industry; elevated teammate turnover or labor costs; the impact of continued increased competition from dialysis providers and others; and our ability to respond to challenging U.S. and global economic and marketplace conditions, including, among other things, our ability to successfully identify cost saving opportunities and to invest in and implement cost saving initiatives;
•the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; a reduction in the number or percentage of our patients under commercial plans, including, without limitation, as a result of continuing legislative efforts to restrict or prohibit the use and/or availability of charitable premium assistance, or as a result of payors implementing restrictive plan designs;
•risks arising from potential changes in or new laws, regulations or requirements applicable to us, including, without limitation, those related to healthcare, antitrust matters, including, among others, non-competes and other restrictive covenants, and acquisition, merger, joint venture or similar transactions and/or labor matters, and potential impacts of changes in enforcement thereof or related litigation impacting, among other things, coverage or reimbursement rates for our services or the number of patients enrolled in or that select higher-paying commercial plans, and the risk that we make incorrect assumptions about how our patients will respond to any such developments;
•our ability to successfully implement our strategies with respect to IKC and VBC initiatives and home based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment;
•a reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid or other government-based programs and the impact of the MA benchmark structure;
5
•our reliance on significant suppliers, service providers and other third party vendors to provide key support to our business operations and enable our provision of services to patients, such as, among others, CHC, Baxter and other suppliers of certain pharmaceuticals, services or critical clinical products; and risks resulting from a closure, reduction or other disruption in the services or products provided to us by such suppliers, service providers and third party vendors, such as the closure of certain Baxter manufacturing facilities following Hurricane Helene;
•noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party, such as the recent cyberattack on CHC, including, among other things, any such non-compliance or breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;
•legal and compliance risks, such as compliance with complex, and at times, evolving government regulations and requirements, and with additional laws that may apply to our operations as we expand geographically or enter into new lines of business;
•our ability to attract, retain and motivate teammates and our ability to manage potential disruptions to our business and operations, including potential work stoppages, operating cost increases or productivity decreases whether due to union organizing activities, legislative or other changes, demand for labor, volatility and uncertainty in the labor market, the current challenging and highly competitive labor market conditions, including due to the ongoing nationwide shortage of skilled clinical personnel or other reasons;
•changes in pharmaceutical practice patterns, reimbursement and payment policies and processes, or pharmaceutical pricing, including with respect to oral phosphate binders, among other things;
•our ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives that, among other things, may erode our patient base and impact reimbursement rates;
•our ability to complete and successfully integrate and operate acquisitions, mergers, dispositions, joint ventures or other strategic transactions on terms favorable to us or at all; and our ability to successfully expand our operations and services in markets outside the United States, or to businesses or products outside of dialysis services;
•the variability of our cash flows, including, without limitation, any extended billing or collections cycles including, without limitation, due to defects or operational issues in our billing systems or in the billing systems or services of third parties on which we rely, such as the operational issues at CHC resulting from a recent cyberattack; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs;
•the effects on us or others of natural or other disasters, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding;
•factors that may impact our ability to repurchase stock under our stock repurchase program and the timing of any such stock repurchases, as well as any use by us of a considerable amount of available funds to repurchase stock;
•our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters, including, among other things, evolving regulatory requirements affecting ESG standards, measurements and reporting requirements; and
•the other risk factors, trends and uncertainties set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024, and the risks and uncertainties discussed in any subsequent reports that we file or furnish with the SEC from time to time.
The financial information presented in this release is unaudited and is subject to change as a result of subsequent events or adjustments, if any, arising prior to the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.
6
DAVITA INC.
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(dollars and shares in thousands, except per share data)
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Dialysis patient service revenues | $ | 3,138,561 | $ | 2,951,950 | $ | 9,141,195 | $ | 8,602,669 | |||||||||||||||
| Other revenues | 125,029 | 169,382 | 379,672 | 391,731 | |||||||||||||||||||
| Total revenues | 3,263,590 | 3,121,332 | 9,520,867 | 8,994,400 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Patient care costs | 2,151,875 | 2,067,315 | 6,373,150 | 6,181,348 | |||||||||||||||||||
| General and administrative | 393,534 | 376,883 | 1,123,859 | 1,072,513 | |||||||||||||||||||
| Depreciation and amortization | 187,014 | 188,423 | 549,758 | 550,166 | |||||||||||||||||||
| Equity investment income, net | (3,711) | (7,228) | (15,874) | (22,502) | |||||||||||||||||||
| Gain on changes in ownership interest | — | — | (35,147) | — | |||||||||||||||||||
| Total operating expenses | 2,728,712 | 2,625,393 | 7,995,746 | 7,781,525 | |||||||||||||||||||
| Operating income | 534,878 | 495,939 | 1,525,121 | 1,212,875 | |||||||||||||||||||
| Debt expense | (134,583) | (98,080) | (331,748) | (302,361) | |||||||||||||||||||
| Debt prepayment, extinguishment and modification costs | (10,081) | — | (19,813) | (7,962) | |||||||||||||||||||
| Other loss, net | (16,780) | (19,650) | (56,900) | (14,525) | |||||||||||||||||||
| Income before income taxes | 373,434 | 378,209 | 1,116,660 | 888,027 | |||||||||||||||||||
| Income tax expense | 77,674 | 68,848 | 215,168 | 161,621 | |||||||||||||||||||
| Net income | 295,760 | 309,361 | 901,492 | 726,406 | |||||||||||||||||||
| Less: Net income attributable to noncontrolling interests | (81,072) | (62,729) | (224,479) | (185,536) | |||||||||||||||||||
| Net income attributable to DaVita Inc. | $ | 214,688 | $ | 246,632 | $ | 677,013 | $ | 540,870 | |||||||||||||||
| Earnings per share attributable to DaVita Inc.: | |||||||||||||||||||||||
| Basic net income | $ | 2.56 | $ | 2.70 | $ | 7.86 | $ | 5.95 | |||||||||||||||
| Diluted net income | $ | 2.50 | $ | 2.62 | $ | 7.66 | $ | 5.80 | |||||||||||||||
| Weighted average shares for earnings per share: | |||||||||||||||||||||||
| Basic shares | 83,721 | 91,322 | 86,123 | 90,937 | |||||||||||||||||||
| Diluted shares | 85,795 | 94,041 | 88,422 | 93,317 | |||||||||||||||||||
7
DAVITA INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited)
(dollars in thousands)
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Net income | $ | 295,760 | $ | 309,361 | $ | 901,492 | $ | 726,406 | |||||||||||||||
| Other comprehensive income (loss), net of tax: | |||||||||||||||||||||||
| Unrealized (losses) gains on interest rate cap agreements: | |||||||||||||||||||||||
| Unrealized (losses) gains | (21,576) | 6,996 | (2,340) | 28,305 | |||||||||||||||||||
| Reclassifications of net realized gains into net income | (1,870) | (21,198) | (45,539) | (55,895) | |||||||||||||||||||
| Unrealized gains (losses) on foreign currency translation: | 56,202 | (47,644) | (62,371) | 27,878 | |||||||||||||||||||
| Other comprehensive income (loss) | 32,756 | (61,846) | (110,250) | 288 | |||||||||||||||||||
| Total comprehensive income | 328,516 | 247,515 | 791,242 | 726,694 | |||||||||||||||||||
| Less: Comprehensive income attributable to noncontrolling interests | (81,072) | (62,729) | (224,479) | (185,536) | |||||||||||||||||||
| Comprehensive income attributable to DaVita Inc. | $ | 247,444 | $ | 184,786 | $ | 566,763 | $ | 541,158 | |||||||||||||||
8
DAVITA INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(dollars in thousands)
| Nine months ended September 30, | |||||||||||
| 2024 | 2023 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net income | $ | 901,492 | $ | 726,406 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 549,758 | 550,166 | |||||||||
| Loss on extinguishment of debt | 12,527 | 7,132 | |||||||||
| Stock-based compensation expense | 75,392 | 82,313 | |||||||||
| Deferred income taxes | (53,713) | (17,767) | |||||||||
| Equity investment loss, net | 91,100 | 40,121 | |||||||||
| Gain on changes in ownership interest | (35,147) | — | |||||||||
| Other non-cash losses, net | 24,159 | 1,633 | |||||||||
| Changes in operating assets and liabilities, net of effect of acquisitions and divestitures: | |||||||||||
| Accounts receivable | (175,643) | 118,148 | |||||||||
| Inventories | 20,495 | 290 | |||||||||
| Other current assets | 72,477 | 31,842 | |||||||||
| Other long-term assets | (12,858) | 1,101 | |||||||||
| Accounts payable | (43,414) | (33,837) | |||||||||
| Accrued compensation and benefits | 27,314 | 65,279 | |||||||||
| Other current liabilities | 35,646 | 10,822 | |||||||||
| Income taxes | (7,528) | (1,878) | |||||||||
| Other long-term liabilities | (7,646) | (7,945) | |||||||||
| Net cash provided by operating activities | 1,474,411 | 1,573,826 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Additions of property and equipment | (384,786) | (409,011) | |||||||||
| Acquisitions | (161,210) | (7,990) | |||||||||
| Proceeds from asset and business sales | 17,937 | 24,907 | |||||||||
| Purchase of debt investments held-to-maturity | (15,319) | (30,419) | |||||||||
| Purchase of other debt and equity investments | (8,784) | (6,693) | |||||||||
| Proceeds from debt investments held-to-maturity | 22,092 | 94,414 | |||||||||
| Proceeds from sale of other debt and equity investments | 4,558 | 3,930 | |||||||||
| Purchase of equity method investments | (4,497) | (276,006) | |||||||||
| Distributions from equity method investments | 6,554 | 3,364 | |||||||||
| Net cash used in investing activities | (523,455) | (603,504) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Borrowings | 6,623,634 | 2,468,335 | |||||||||
| Payments on long-term debt | (5,437,907) | (2,992,248) | |||||||||
| Deferred and debt related financing costs | (46,011) | (53,466) | |||||||||
| Purchase of treasury stock | (1,020,550) | — | |||||||||
| Distributions to noncontrolling interests | (229,236) | (203,381) | |||||||||
| Net payments related to stock purchases and awards | (112,496) | (41,155) | |||||||||
| Contributions from noncontrolling interests | 10,623 | 11,579 | |||||||||
| Proceeds from sales of additional noncontrolling interests | 860 | 50,962 | |||||||||
| Purchases of noncontrolling interests | (40,751) | (7,875) | |||||||||
| Net cash used in financing activities | (251,834) | (767,249) | |||||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (5,112) | 3,063 | |||||||||
| Net increase in cash, cash equivalents and restricted cash | 694,010 | 206,136 | |||||||||
| Cash, cash equivalents and restricted cash at beginning of the year | 464,634 | 338,989 | |||||||||
| Cash, cash equivalents and restricted cash at end of the period | $ | 1,158,644 | $ | 545,125 | |||||||
9
DAVITA INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(dollars and shares in thousands, except per share data)
| September 30, 2024 | December 31, 2023 | ||||||||||
| ASSETS | |||||||||||
| Cash and cash equivalents | $ | 1,070,775 | $ | 380,063 | |||||||
| Restricted cash and equivalents | 87,869 | 84,571 | |||||||||
| Short-term investments | 20,996 | 11,610 | |||||||||
| Accounts receivable | 2,267,365 | 1,986,856 | |||||||||
| Inventories | 128,999 | 143,105 | |||||||||
| Other receivables | 359,485 | 422,669 | |||||||||
| Prepaid and other current assets | 96,989 | 102,645 | |||||||||
| Income tax receivable | 4,522 | 6,387 | |||||||||
| Total current assets | 4,037,000 | 3,137,906 | |||||||||
Property and equipment, net of accumulated depreciation of $6,174,254 and $5,759,514, respectively | 2,939,620 | 3,073,533 | |||||||||
| Operating lease right-of-use assets | 2,418,350 | 2,501,364 | |||||||||
Intangible assets, net of accumulated amortization of $29,374 and $38,445, respectively | 197,854 | 203,224 | |||||||||
| Equity method and other investments | 430,483 | 545,848 | |||||||||
| Long-term investments | 33,844 | 47,890 | |||||||||
| Other long-term assets | 218,956 | 271,253 | |||||||||
| Goodwill | 7,227,630 | 7,112,560 | |||||||||
| $ | 17,503,737 | $ | 16,893,578 | ||||||||
| LIABILITIES AND EQUITY | |||||||||||
| Accounts payable | $ | 488,244 | $ | 514,533 | |||||||
| Other liabilities | 927,530 | 828,878 | |||||||||
| Accrued compensation and benefits | 806,149 | 752,598 | |||||||||
| Current portion of operating lease liabilities | 404,540 | 394,399 | |||||||||
| Current portion of long-term debt | 296,255 | 123,299 | |||||||||
| Income tax payable | 21,268 | 28,507 | |||||||||
| Total current liabilities | 2,943,986 | 2,642,214 | |||||||||
| Long-term operating lease liabilities | 2,237,135 | 2,330,389 | |||||||||
| Long-term debt | 9,260,331 | 8,268,334 | |||||||||
| Other long-term liabilities | 183,030 | 183,074 | |||||||||
| Deferred income taxes | 659,581 | 726,217 | |||||||||
| Total liabilities | 15,284,063 | 14,150,228 | |||||||||
| Commitments and contingencies | |||||||||||
| Noncontrolling interests subject to put provisions | 1,633,011 | 1,499,288 | |||||||||
| Equity: | |||||||||||
Preferred stock ($0.001 par value, 5,000 shares authorized; none issued) | — | — | |||||||||
Common stock ($0.001 par value, 450,000 shares authorized; 90,132 and 82,624 shares issued and outstanding at September 30, 2024, respectively, and 88,824 shares issued and outstanding at December 31, 2023) | 90 | 89 | |||||||||
| Additional paid-in capital | 295,637 | 509,804 | |||||||||
| Retained earnings | 1,275,301 | 598,288 | |||||||||
Treasury stock (7,508 and zero shares, respectively) | (1,021,979) | — | |||||||||
| Accumulated other comprehensive loss | (162,334) | (52,084) | |||||||||
| Total DaVita Inc. shareholders' equity | 386,715 | 1,056,097 | |||||||||
| Noncontrolling interests not subject to put provisions | 199,948 | 187,965 | |||||||||
| Total equity | 586,663 | 1,244,062 | |||||||||
| $ | 17,503,737 | $ | 16,893,578 | ||||||||
10
DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA
(unaudited)
(dollars in millions and shares in thousands, except per treatment and patient data)
(dollars in millions and shares in thousands, except per treatment and patient data)
| Three months ended | Nine months ended September 30, 2024 | ||||||||||||||||
| September 30, 2024 | June 30, 2024 | ||||||||||||||||
| 1. Consolidated business metrics: | |||||||||||||||||
| Operating margin | 16.4 | % | 15.9 | % | 16.0 | % | |||||||||||
Adjusted operating margin excluding certain items(2) | 16.4 | % | 15.9 | % | 15.6 | % | |||||||||||
General and administrative expenses as a percent of consolidated revenues(1) | 12.1 | % | 11.5 | % | 11.8 | % | |||||||||||
Effective income tax rate on income | 20.8 | % | 19.3 | % | 19.3 | % | |||||||||||
Effective income tax rate on income attributable to DaVita Inc.(2) | 26.5 | % | 24.2 | % | 24.1 | % | |||||||||||
Effective income tax rate on adjusted income attributable to DaVita Inc.(2) | 26.5 | % | 24.3 | % | 25.0 | % | |||||||||||
| 2. Summary of financial results: | |||||||||||||||||
| Revenues: | |||||||||||||||||
U.S. dialysis patient services and other | $ | 2,906 | $ | 2,841 | $ | 8,503 | |||||||||||
Other—Ancillary services | |||||||||||||||||
| Integrated kidney care | 112 | 114 | 342 | ||||||||||||||
| Other U.S. ancillary | 6 | 7 | 20 | ||||||||||||||
International dialysis patient service and other | 258 | 242 | 719 | ||||||||||||||
| 376 | 362 | 1,080 | |||||||||||||||
Eliminations | (19) | (17) | (63) | ||||||||||||||
Total consolidated revenues | $ | 3,264 | $ | 3,187 | $ | 9,521 | |||||||||||
| Operating income (loss): | |||||||||||||||||
U.S. dialysis | $ | 549 | $ | 550 | $ | 1,625 | |||||||||||
Other—Ancillary services | |||||||||||||||||
| Integrated kidney care | (2) | (34) | (62) | ||||||||||||||
| Other U.S. ancillary | (2) | (2) | (6) | ||||||||||||||
International(3) | 18 | 17 | 51 | ||||||||||||||
| 14 | (19) | (16) | |||||||||||||||
Corporate administrative support expenses | (29) | (25) | (84) | ||||||||||||||
Total consolidated operating income | $ | 535 | $ | 506 | $ | 1,525 | |||||||||||
11
DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA - continued
(unaudited)
(dollars in millions and shares in thousands, except per treatment and patient data)
| Three months ended | Nine months ended September 30, 2024 | ||||||||||||||||
| September 30, 2024 | June 30, 2024 | ||||||||||||||||
| 3. Summary of reportable segment financial results and metrics: | |||||||||||||||||
U.S. dialysis | |||||||||||||||||
| Financial results | |||||||||||||||||
Revenue: | |||||||||||||||||
Dialysis patient service revenues | $ | 2,900 | $ | 2,835 | $ | 8,485 | |||||||||||
Other revenues | 6 | 6 | 18 | ||||||||||||||
Total operating revenues | 2,906 | 2,841 | 8,503 | ||||||||||||||
Operating expenses: | |||||||||||||||||
Patient care costs | 1,893 | 1,855 | 5,572 | ||||||||||||||
General and administrative | 301 | 282 | 858 | ||||||||||||||
Depreciation and amortization | 171 | 160 | 504 | ||||||||||||||
Equity investment income | (8) | (6) | (20) | ||||||||||||||
| Gain on changes in ownership interests | — | — | (35) | ||||||||||||||
Total operating expenses | 2,357 | 2,291 | 6,878 | ||||||||||||||
| Segment operating income | $ | 549 | $ | 550 | $ | 1,625 | |||||||||||
Reconciliation for non-GAAP measure: | |||||||||||||||||
Gain on changes in ownership interest | — | — | (35) | ||||||||||||||
Adjusted segment operating income(2) | $ | 549 | $ | 550 | $ | 1,590 | |||||||||||
| Metrics | |||||||||||||||||
Volume: | |||||||||||||||||
| Treatments | 7,350,784 | 7,265,444 | 21,767,740 | ||||||||||||||
| Number of treatment days | 79.0 | 78.0 | 234.6 | ||||||||||||||
| Average treatments per day | 93,048 | 93,147 | 92,787 | ||||||||||||||
| Per day year-over-year increase | 0.6 | % | 0.5 | % | 0.3 | % | |||||||||||
Normalized year-over-year non-acquired treatment growth(4) | (0.2) | % | 0.4 | % | |||||||||||||
Operating net revenues: | |||||||||||||||||
| Average patient service revenue per treatment | $ | 394.49 | $ | 390.22 | $ | 389.79 | |||||||||||
Expenses: | |||||||||||||||||
Patient care costs per treatment | $ | 257.46 | $ | 255.25 | $ | 255.96 | |||||||||||
| General and administrative expenses per treatment | $ | 41.01 | $ | 38.79 | $ | 39.41 | |||||||||||
| Depreciation and amortization expense per treatment | $ | 23.21 | $ | 22.08 | $ | 23.14 | |||||||||||
| Accounts receivable: | |||||||||||||||||
Receivables | $ | 1,707 | $ | 1,812 | |||||||||||||
DSO | 54 | 59 | |||||||||||||||
| 4. IKC metrics: | |||||||||||||||||
| Patients per integrated care arrangement type: | |||||||||||||||||
| Risk-based | 69,500 | 71,300 | |||||||||||||||
| Other | 13,900 | 15,200 | |||||||||||||||
Annualized aggregate risk based spend(7) | $ | 5,400 | $ | 5,400 | |||||||||||||
12
DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA - continued
(unaudited)
(dollars in millions and shares in thousands, except per treatment and patient data)
| Three months ended | Nine months ended September 30, 2024 | ||||||||||||||||
| September 30, 2024 | June 30, 2024 | ||||||||||||||||
| 5. Cash flow: | |||||||||||||||||
| Operating cash flow | $ | 810 | $ | 799 | $ | 1,474 | |||||||||||
| Operating cash flow, last twelve months | $ | 1,960 | $ | 1,810 | |||||||||||||
Free cash flow(2) | $ | 555 | $ | 654 | $ | 882 | |||||||||||
Free cash flow, last twelve months(2) | $ | 1,139 | $ | 1,038 | |||||||||||||
| Capital expenditures: | |||||||||||||||||
| Maintenance | $ | 104 | $ | 86 | $ | 275 | |||||||||||
| Development | $ | 35 | $ | 39 | $ | 110 | |||||||||||
Acquisition expenditures | $ | 3 | $ | 53 | $ | 161 | |||||||||||
| Proceeds from sale of self-developed properties | $ | 2 | $ | 6 | $ | 11 | |||||||||||
| 6. Debt and capital structure: | |||||||||||||||||
Total debt(5) | $ | 9,624 | $ | 9,048 | |||||||||||||
Net debt, net of cash and cash equivalents(5) | $ | 8,553 | $ | 8,632 | |||||||||||||
Leverage ratio(6) | 3.17x | 3.10x | |||||||||||||||
| Weighted average effective interest rate: | |||||||||||||||||
During the quarter | 5.69 | % | 4.27 | % | |||||||||||||
At end of the quarter | 5.71 | % | 4.33 | % | |||||||||||||
| On the senior secured credit facilities at end of the quarter | 7.01 | % | 4.62 | % | |||||||||||||
| Debt with fixed and capped rates as a percentage of total debt: | |||||||||||||||||
Debt with rates fixed by its terms | 59 | % | 55 | % | |||||||||||||
| Debt with rates fixed by its terms or capped by cap agreements | 95 | % | 93 | % | |||||||||||||
| Amount spent on share repurchases | $ | 406 | $ | 376 | $ | 1,022 | |||||||||||
| Number of shares repurchased | 2,734 | 2,655 | 7,508 | ||||||||||||||
Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.
(1)General and administrative expenses include certain corporate support, long-term incentive compensation and advocacy costs.
(2)These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, and for a definition of adjusted amounts, see attached reconciliation schedules. Adjusted operating income margin is adjusted operating income divided by consolidated revenues.
(3)The reported operating income for the three months ended September 30, 2024 and June 30, 2024, and for nine months ended September 30, 2024 includes foreign currency (losses) gains embedded in equity method income recognized from our Asia Pacific joint venture of approximately $(3.7), $0.4 and $(1.8), respectively.
(4)Normalized non-acquired treatment growth reflects year-over-year growth in treatment volume, adjusted to exclude acquisitions and other similar transactions, and further adjusted to normalize for the number and mix of treatment days in a given quarter versus the prior year quarter.
(5)The debt amounts as of September 30, 2024 and June 30, 2024 presented exclude approximately $67.2 and $58.6, respectively, of debt discount, premium and other deferred financing costs related to our senior secured credit facilities and senior notes in effect or outstanding at that time.
(6)This is a non-GAAP measure. See "Calculation of Leverage Ratio" in non-GAAP reconciliations.
(7)Integrated care metrics: The aggregate amount of medical spend associated with risk-based integrated care arrangements that we disclose includes both medical costs included in our reported expenses for certain risk-based arrangements (such as our SNPs), as well as the aggregate estimated benchmark amount above or below which we will incur profit or loss from VBC arrangements under which third-party medical costs are not included in our reported results.
13
DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES
(unaudited)
(dollars in millions)
Calculation of the Leverage Ratio
Under our amended senior secured credit facilities (the Amended Credit Agreement) dated August 13, 2024 and our prior senior secured credit facilities, the leverage ratio is defined as (a) all funded debt, minus unrestricted cash and cash equivalents (including short-term investments) not to exceed $750 divided by (b) "Consolidated EBITDA." The leverage ratio determines the interest rate margin payable by the Company for its Term Loan A-1 and revolving line of credit under the Amended Credit Agreement by establishing the margin over the base interest rate (SOFR plus credit spread adjustment) that is applicable. The calculation below is based on the last 12 months of "Consolidated EBITDA" and "Consolidated net debt" at the end of each reported period, each as defined in the credit agreement. The calculation of "Consolidated EBITDA" below sets forth, among other things, certain pro forma adjustments described in the Amended Credit Agreement, including pro forma adjustments for acquisitions or divestitures that occurred during the period and certain projected net cost savings, expense reductions and cost synergies. These pro forma adjustments are determined according to specified criteria set forth in the Amended Credit Agreement, and as a result, the total adjustments calculated may not be comparable to the Company's estimates for other purposes, including as operating performance measures. The Company's management believes the presentation of "Consolidated EBITDA" is useful to investors to enhance their understanding of the Company's leverage ratio under the Amended Credit Agreement and should not be evaluated for any other purpose. The leverage ratio calculated by the Company is a non-GAAP measure and should not be considered a substitute for the ratio of total debt to operating income, determined in accordance with GAAP. The Company's calculation of its leverage ratio might not be calculated in the same manner as, and thus might not be comparable to, similarly titled measures of other companies.
| Twelve months ended | |||||||||||
| September 30, 2024 | June 30, 2024 | ||||||||||
| Net income attributable to DaVita Inc. | $ | 828 | $ | 860 | |||||||
| Income taxes | 274 | 265 | |||||||||
| Interest expense | 375 | 348 | |||||||||
| Depreciation and amortization | 745 | 746 | |||||||||
| Impairment charges | 26 | 26 | |||||||||
| Net income attributable to noncontrolling interests | 304 | 286 | |||||||||
| Stock-settled stock-based compensation | 101 | 103 | |||||||||
| Debt extinguishment and modification costs | 20 | 10 | |||||||||
| Expected cost savings and expense reductions | 15 | 16 | |||||||||
| Severance and other related costs | — | 5 | |||||||||
| Other | 112 | 116 | |||||||||
| "Consolidated EBITDA" | $ | 2,801 | $ | 2,781 | |||||||
| September 30, 2024 | June 30, 2024 | ||||||||||
Total debt, excluding debt discount and other deferred financing costs(1) | $ | 9,624 | $ | 9,048 | |||||||
Less: Cash and cash equivalents including short-term investments(2) | (750) | (432) | |||||||||
| Consolidated net debt | $ | 8,874 | $ | 8,616 | |||||||
| Last twelve months "Consolidated EBITDA" | $ | 2,801 | $ | 2,781 | |||||||
| Leverage ratio | 3.17x | 3.10x | |||||||||
| Maximum leverage ratio permitted under the Credit Agreement | 5.00x | 5.00x | |||||||||
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
(1)The debt amounts as of September 30, 2024 and June 30, 2024 presented exclude approximately $67.2 and $58.6, respectively, of debt discount, premium and other deferred financing costs related to our senior secured credit facilities and senior notes in effect or outstanding at that time.
(2)This excludes amounts not readily convertible to cash related to the Company's non-qualified deferred compensation plans for all periods presented. The Amended Credit Agreement limits the amount deducted for cash and cash equivalents, including short-term investments, to the lesser of all unrestricted cash and cash equivalents, including short-term investments of the Company or $750.
14
DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES
(unaudited)
Note on Non-GAAP Financial Measures
As used in this press release, the term "adjusted" refers to non-GAAP measures as follows, each as reconciled to its most comparable GAAP measure as presented in the non-GAAP reconciliations in the notes to this press release: (i) for income and expense measures, the term "adjusted" refers to operating performance measures that exclude certain items such as, but not limited to, impairment charges, (gain) loss on ownership changes, restructuring charges, accruals for legal matters, and debt extinguishment and modification costs; and (ii) the term "effective income tax rate on adjusted income attributable to DaVita Inc." represents the Company’s effective tax rate excluding applicable non-GAAP items and the tax associated with them as well as noncontrolling owners’ income, which primarily relates to non-tax paying entities.
In connection with a comment letter from the Securities and Exchange Commission Staff, beginning in the second quarter of 2024, we have updated the presentation of our non-GAAP measures to no longer exclude center closure costs for all periods presented. To facilitate comparisons, the non-GAAP measures presented for prior periods also have been conformed to the presentation of the non-GAAP measures for the current period.
These non-GAAP or "adjusted" measures are presented because management believes these measures are useful adjuncts to GAAP results. However, these non-GAAP measures should not be considered alternatives to the corresponding measures determined under GAAP.
Specifically, management uses adjusted measures of operating expenses for its U.S. dialysis business, adjusted U.S. dialysis patient care costs per treatment, adjusted operating income, adjusted net income attributable to DaVita Inc. and adjusted diluted net income per share attributable to DaVita Inc. to compare and evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe these non-GAAP measures also are useful to investors and analysts in evaluating our performance over time and relative to competitors, as well as in analyzing the underlying trends in our business. Furthermore, we believe these presentations enhance a user's understanding of our normal consolidated results by excluding certain items which we do not believe are indicative of our ordinary results of operations. As a result, adjusting for these amounts allows for comparison to our normalized prior period results.
The effective income tax rate on adjusted income attributable to DaVita Inc. excludes noncontrolling owners' income and certain non-deductible and other charges which we do not believe are indicative of our ordinary results. Accordingly, we believe these adjusted effective income tax rates are useful to management, investors and analysts in evaluating our performance and establishing expectations for income taxes incurred on our ordinary results attributable to DaVita Inc.
Finally, free cash flow represents net cash provided by operating activities less distributions to noncontrolling interests, development capital expenditures, and maintenance capital expenditures; plus contributions from noncontrolling interests and proceeds from the sale of self-developed properties. Management uses this measure to assess our ability to fund acquisitions and meet our debt service obligations and we believe this measure is equally useful to investors and analysts as an adjunct to cash flows from operating activities and other measures under GAAP.
It is important to bear in mind that these non-GAAP "adjusted" measures are not measures of financial performance or liquidity under GAAP and should not be considered in isolation from, nor as substitutes for, their most comparable GAAP measures.
The following reconciliations of the non-GAAP financial measures presented in this press release to their most comparable GAAP measures.
15
DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES - continued
(unaudited)
(dollars in millions, except per share data)
Adjusted net income and adjusted diluted net income per share attributable to DaVita Inc.:
| Three months ended | Nine months ended | ||||||||||||||||||||||||||||||||||||||||||||||
| September 30, 2024 | June 30, 2024 | September 30, 2024 | September 30, 2023 | ||||||||||||||||||||||||||||||||||||||||||||
| Dollars | Per share | Dollars | Per share | Dollars | Per share | Dollars | Per share | ||||||||||||||||||||||||||||||||||||||||
| Consolidated: | |||||||||||||||||||||||||||||||||||||||||||||||
| Net income attributable to DaVita Inc. | $ | 215 | $ | 2.50 | $ | 223 | $ | 2.50 | $ | 677 | $ | 7.66 | $ | 541 | $ | 5.80 | |||||||||||||||||||||||||||||||
Legal matter(1) | — | — | — | — | — | — | 11 | 0.12 | |||||||||||||||||||||||||||||||||||||||
Gain on changes in ownership interest(2) | — | — | — | — | (35) | (0.40) | — | — | |||||||||||||||||||||||||||||||||||||||
Severance and other costs(3) | — | — | — | — | — | — | 28 | 0.30 | |||||||||||||||||||||||||||||||||||||||
Debt prepayment and refinancing charges(4) | 10 | 0.12 | 10 | 0.11 | 20 | 0.22 | 8 | 0.09 | |||||||||||||||||||||||||||||||||||||||
Other income - Mozarc gain(5) | — | — | — | — | — | — | (14) | (0.15) | |||||||||||||||||||||||||||||||||||||||
| Related income tax | (3) | (0.03) | (2) | (0.03) | (5) | (0.06) | (8) | (0.09) | |||||||||||||||||||||||||||||||||||||||
Adjusted net income attributable to DaVita Inc.(6) | $ | 222 | $ | 2.59 | $ | 230 | $ | 2.59 | $ | 657 | $ | 7.43 | $ | 566 | $ | 6.06 | |||||||||||||||||||||||||||||||
Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.
Adjusted operating income:
| Three months ended September 30, 2024 | |||||||||||||||||||||||||||||||||||||||||
| U.S. dialysis | Ancillary services | Corporate administration | |||||||||||||||||||||||||||||||||||||||
| U.S. IKC | U.S. Other | International | Total | Consolidated | |||||||||||||||||||||||||||||||||||||
| Operating income (loss) | $ | 549 | $ | (2) | $ | (2) | $ | 18 | $ | 14 | $ | (29) | $ | 535 | |||||||||||||||||||||||||||
Adjusted operating income (loss)(6) | $ | 549 | $ | (2) | $ | (2) | $ | 18 | $ | 14 | $ | (29) | $ | 535 | |||||||||||||||||||||||||||
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
| Three months ended June 30, 2024 | |||||||||||||||||||||||||||||||||||||||||
| U.S. dialysis | Ancillary services | Corporate administration | |||||||||||||||||||||||||||||||||||||||
| U.S. IKC | U.S. Other | International | Total | Consolidated | |||||||||||||||||||||||||||||||||||||
| Operating income (loss) | $ | 550 | $ | (34) | $ | (2) | $ | 17 | $ | (19) | $ | (25) | $ | 506 | |||||||||||||||||||||||||||
Adjusted operating income (loss)(6) | $ | 550 | $ | (34) | $ | (2) | $ | 17 | $ | (19) | $ | (25) | $ | 506 | |||||||||||||||||||||||||||
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
| Nine months ended September 30, 2024 | |||||||||||||||||||||||||||||||||||||||||
| U.S. dialysis | Ancillary services | Corporate administration | |||||||||||||||||||||||||||||||||||||||
| U.S. IKC | U.S. Other | International | Total | Consolidated | |||||||||||||||||||||||||||||||||||||
| Operating income (loss) | $ | 1,625 | $ | (62) | $ | (6) | $ | 51 | $ | (16) | $ | (84) | $ | 1,525 | |||||||||||||||||||||||||||
Gain on changes in ownership interest(2) | (35) | — | — | — | — | — | (35) | ||||||||||||||||||||||||||||||||||
Adjusted operating income (loss)(6) | $ | 1,590 | $ | (62) | $ | (6) | $ | 51 | $ | (16) | $ | (84) | $ | 1,490 | |||||||||||||||||||||||||||
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
| Nine months ended September 30, 2023 | |||||||||||||||||||||||||||||||||||||||||
| U.S. dialysis | Ancillary services | Corporate administration | |||||||||||||||||||||||||||||||||||||||
| U.S. IKC | U.S. Other | International | Total | Consolidated | |||||||||||||||||||||||||||||||||||||
| Operating income (loss) | $ | 1,331 | $ | (66) | $ | (7) | $ | 54 | $ | (18) | $ | (100) | $ | 1,213 | |||||||||||||||||||||||||||
Legal matter(1) | — | — | — | — | — | 11 | 11 | ||||||||||||||||||||||||||||||||||
Severance and other costs(3) | 26 | — | — | — | — | 1 | 28 | ||||||||||||||||||||||||||||||||||
Adjusted operating income (loss)(6) | $ | 1,357 | $ | (65) | $ | (7) | $ | 54 | $ | (18) | $ | (87) | $ | 1,252 | |||||||||||||||||||||||||||
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
16
DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES - continued
(unaudited)
(dollars in millions, except per share data)
Effective income tax rates:
| Three months ended | Nine months ended September 30, 2024 | ||||||||||||||||
| September 30, 2024 | June 30, 2024 | ||||||||||||||||
| Effective income tax rates on income attributable to DaVita Inc.: | |||||||||||||||||
| Income before income taxes | $ | 373 | $ | 371 | $ | 1,117 | |||||||||||
| Noncontrolling owners’ income primarily attributable to non-tax paying entities | (81) | (78) | (225) | ||||||||||||||
| Income before income taxes attributable to DaVita Inc. | $ | 292 | $ | 294 | $ | 892 | |||||||||||
| Income tax expense | $ | 78 | $ | 72 | $ | 215 | |||||||||||
| Income tax attributable to noncontrolling interests | — | — | (1) | ||||||||||||||
| Income tax expense attributable to DaVita Inc. | $ | 78 | $ | 71 | $ | 215 | |||||||||||
| Effective income tax rate on income attributable to DaVita Inc. | 26.5 | % | 24.2 | % | 24.1 | % | |||||||||||
| Effective income tax rate on adjusted income attributable to DaVita Inc.: | |||||||||||||||||
| Income before income taxes | $ | 373 | $ | 371 | $ | 1,117 | |||||||||||
Gain on changes in ownership interest(2) | — | — | (35) | ||||||||||||||
Debt prepayment and refinancing charges(4) | 10 | 10 | 20 | ||||||||||||||
| Noncontrolling owners’ income primarily attributable to non-tax paying entities | (81) | (78) | (225) | ||||||||||||||
Adjusted income before income taxes attributable to DaVita Inc.(6) | $ | 302 | $ | 304 | $ | 876 | |||||||||||
| Income tax expense | $ | 78 | $ | 72 | $ | 215 | |||||||||||
| Plus income tax related to: | |||||||||||||||||
Debt prepayment and refinancing charges(4) | 3 | 2 | 5 | ||||||||||||||
| Less income tax related to: | |||||||||||||||||
| Noncontrolling interests | — | — | (1) | ||||||||||||||
Income tax on adjusted income attributable to DaVita Inc.(6) | $ | 80 | $ | 74 | $ | 219 | |||||||||||
Effective income tax rate on adjusted income attributable to DaVita Inc.(6) | 26.5 | % | 24.3 | % | 25.0 | % | |||||||||||
Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.
Free cash flow:
| Three months ended | Nine months ended September 30, 2024 | ||||||||||||||||||||||
| September 30, 2024 | June 30, 2024 | September 30, 2023 | |||||||||||||||||||||
| Net cash provided by (used in) operating activities | $ | 810 | $ | 799 | $ | 661 | $ | 1,474 | |||||||||||||||
| Adjustments to reconcile net cash provided by operating activities to free cash flow: | |||||||||||||||||||||||
| Distributions to noncontrolling interests | (122) | (30) | (79) | (229) | |||||||||||||||||||
| Contributions from noncontrolling interests | 3 | 4 | 5 | 11 | |||||||||||||||||||
Maintenance capital expenditures(7) | (104) | (86) | (93) | (275) | |||||||||||||||||||
Development capital expenditures(8) | (35) | (39) | (44) | (110) | |||||||||||||||||||
| Proceeds from sale of self-developed properties | 2 | 6 | 4 | 11 | |||||||||||||||||||
| Free cash flow | $ | 555 | $ | 654 | $ | 453 | $ | 882 | |||||||||||||||
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
17
DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES - continued
(unaudited)
(dollars in millions, except per share data)
| Twelve months ended | |||||||||||||||||
| September 30, 2024 | June 30, 2024 | September 30, 2023 | |||||||||||||||
| Net cash provided by operating activities | $ | 1,960 | $ | 1,810 | $ | 1,918 | |||||||||||
| Adjustments to reconcile net cash provided by operating activities to free cash flow: | |||||||||||||||||
| Distributions to noncontrolling interests | (307) | (264) | (283) | ||||||||||||||
| Contributions from noncontrolling interests | 14 | 15 | 15 | ||||||||||||||
Maintenance capital expenditures(7) | (394) | (383) | (434) | ||||||||||||||
Development capital expenditures(8) | (150) | (158) | (169) | ||||||||||||||
| Proceeds from sale of self-developed properties | 16 | 18 | 7 | ||||||||||||||
| Free cash flow | $ | 1,139 | $ | 1,038 | $ | 1,054 | |||||||||||
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
(1)Represents an accrual for potential third-party settlement costs for the matter further described in Note 8 to our condensed consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 under the heading “2017 U.S. Attorney Colorado Investigation” We have excluded this charge, which had been previously disclosed, from our non-GAAP metrics because, among other things, we do not believe it is indicative of our ordinary results of operations. In this instance, among the factors considered were that the claim relates to prior ancillary operations or activities that the Company sold or closed (or otherwise ceased) prior to June 2020, and the charge is significant and may obscure analysis of underlying trends and financial performance of our current business.
(2)Represents a non-cash gain recognized on the acquisition of a controlling financial interest in a previously nonconsolidated dialysis partnership. This gain to mark the investment to fair value prior to consolidation does not represent a normal and recurring cost of operating our business or generating revenues and may obscure analysis of underlying trends and financial performance.
(3)Includes severance and other termination costs related to a prior strategic restructuring initiative and associated transition of certain general and administrative support functions to a third party.
(4)Represents the non-cash write-off of debt refinancing costs associated with the Company's senior secured credit agreement. Costs associated with refinancing the Company's debt are not indicative of normal debt expense and may obscure analysis of underlying trends and financial performance. See additional discussion under "Debt transactions" above.
(5)Represents a non-cash gain recognized on rights contributed to Mozarc Medical Holding LLC (Mozarc) upon its formation. This gain to mark these rights to fair value prior to contribution to Mozarc does not represent a normal and recurring cost of operating our business or generating revenues and may obscure analysis of underlying trends and financial performance.
(6)In connection with the conclusion of a comment letter from the Securities and Exchange Commission Staff in July 2024, beginning in the second quarter of 2024, we have updated our non-GAAP measures to no longer exclude center closure costs for all periods presented. To facilitate comparisons, the non-GAAP measures presented for prior periods also have been conformed to the presentation of the non-GAAP measures for the current period.
(7)Maintenance capital expenditures represent capital expenditures to maintain the productive capacity of the business and include those made for investments in information technology, dialysis center renovations, capital asset replacements, and any other capital expenditures that are not development or acquisition expenditures.
(8)Development capital expenditures principally represent capital expenditures (other than acquisition expenditures) made to expand the productive capacity of the business and include those for new U.S. and international dialysis center developments, dialysis center expansions and relocations, and new or expanded contracted hospital operations.
18